Zaburzenia metabolizmu glukozy wykryte w doustnym teście obciążenia glukozą u chorych z zawałem serca: znaczenie kliniczne, epidemiologia, przebieg naturalny i problemy terapeutyczne Two-hour post load glycemia (2h-PG) obtained during the oral glucose tolerance test (OGTT) is related to adverse cardiovascular outcomes more significantly than fasting glycemia, and the association of 2h-PG with cardiovascular morbidity is graded and independent. An abnormal value of 2h-PG is defined as glycemia ≥ 7.8 mmol/l (140 mg/dl) in most studies. Patients with acute myocardial infarction with abnormal 2h-PG compared to patients with normal 2h-PG have a significantly higher long-term mortality and more concomitant diseases, however, it has not been shown that those subjects have a higher risk of myocardial infarction, coronary revascularization or stroke. Studies have shown that in some patients the glucometabolic status changes after the acute phase of the disease, and that those changes have a prognostic importance. In this review article the authors presented the significance, epidemiology, natural course of glucometabolic disturbances and the therapeutic concerns of hypoglycemic treatment.
ST R ES ZCZ E NI E
W porównaniu z glikemią na czczo, wartość glikemii po dwóch godzinach (2h-PG) uzyskana w doustnym teście obciążenia glukozą (OGTT) jest parametrem lepiej korelującym z przyszłymi niekorzystnymi zdarzeniami sercowo--naczyniowymi, a jej związek z zapadalnością na chorobę wieńcową oraz ze śmiertelnością jest stopniowy i niezależny. Nieprawidłowy wynik 2h-PG w większości publikowanych prac definiuje się jako ≥ 7,8 mmol/l (140 mg/dl). U chorych z zawałem serca, u których stwierdza się nieprawidłowy wynik 2h-PG, w porównaniu z chorymi z prawidłowym 2h-PG, rokowanie jest gorsze. Charakteryzują się również częstszym występowaniem chorób towarzyszących. Są to pacjenci, których śmiertelność odległa jest znamiennie wyższa, jednak dotychczas nie wykazano jednoznacznie, aby byli to chorzy, u których częściej występuje ponowny zawał serca, rewaskularyzacja wieńcowa czy udar mózgu. Wskazuje się również na fakt, iż u części chorych stan glukometaboliczny zmienia się po ostrej fazie choroby, co ma wpływ na śmiertelność. W prezentowanej pracy przedstawiono znaczenie zaburzeń metabolizmu glukozy, ich epidemiologię, przebieg naturalny oraz poruszono problem leczenia hipoglikemizującego.
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INT RO D UCT IO N
Hyperglycemia is one of the main concerns of public health. The risk of this abnormal glucometabolic state, related complications, and its clinical importance have been widely discussed and investigated for several decades. Patients with hyperglycemia are at high risk of cardiovascular disease and mortalitya worldwide problem that has not only not been resolved, but continues to worsen. There are various parameters used to detect disturbances in glucose metabolism, however, the two-hour post load glycemia (2h-PG) obtained during the oral glucose tolerance test (OGTT) is valuable for the evaluation of glucometabolic status and risk stratification in the general population and in patients with coronary artery disease [1, 2, 3, 4] . 2h-PG is superior to fasting glucose in assessing the risk of future cardiovascular events, and the relation of 2h-PG to coronary heart disease incidence and cardiovascular morality is graded and independent [5] . Increased mortality was observed in people with abnormal glucose tolerance detected by 2h-PG, but not in subjects with impaired fasting glycemia, and a high 2h-PG predicted all-cause and cardiovascular mortality after adjustment for other risk factors, while a high fasting glucose was not predictive once 2h-PG was taken into account [6, 7] . It should be noted that in patients with abnormal 2h-PG and normal fasting glucose, the risk of death is underestimated [8] . Elevated 2h-PG was also found to be a risk factor of mortality, independent of the levels of glycosylated hemoglobin (HbA1c), although HBA1c was a prognostic factor in patients with acute myocardial infarction (AMI) and newly detected glucose abnormalities [9, 10] . The most recent guidelines dedicated to the topic of diabetes, pre-dia-betes and cardiovascular disease published by the European Society of Cardiology (ESC) recommend fasting glycemia and HbA1c as primary screening methods, but also advocated OGTT as the preferred one to detect glucose abnormalities in patients with acute coronary syndrome [11] . The aim of this review article is to expound the important role of the oral glucose tolerance test in a very high risk population of patients with acute myocardial infarction.
Value of oral glucose tolerance test in acute phase of acute myocardial infarctionprevalence and significance of glucose abnormalities
In the studies which are cited below, the prevalence of abnormal glucose tolerance in the acute phase of AMI was 25-66%, of DM it was 16-40%, of IGT 22-41%. Impaired fasting glycemia (isolated or coexisting with impaired glucose tolerance) was observed in 10-15%, but it was reported infrequently. In patients with coronary artery disease, 2h-PG has a similar diagnostic and prognostic usefulness as in other populations [12, 13, 14, 15, 16, 17, 18] . Tamita et al. classified AMI patients with respect to fasting glucose as subjects with normal or impaired fasting glycemia and showed that there were no significant differences in the major adverse cardiovascular events (MACE) between those groups. However, when patients were divided with respect to 2h-PG into subjects with abnormal glucose tolerance (AGT; 2h-PG ≥ 7.8 mmol/l) and normal glucose tolerance (NGT; 2h-PG < 7.8 mmol/l) the MACE rate was significantly higher in the AGT group [15] . The authors stated that the post-challenge glucometabolic status is a better risk factor for future cardiovascular events than the fasting glucose level and may critically distinguish high-risk individuals [15] . Kitada et al. presented receiver-operator charac-teristic curves which indicated that a cut-off value of 2h-PG ≥ 160 mg/dL best predicted MACE in patients without previously known diabetes. This measure of post-load glycemia showed a sensitivity and specificity of 59% and 58%, respectively. However, impaired glucose tolerance (IGT, defined as 2h-PG < 11.1 and ≥ 7.8 mmol/l) was associated with a similar prognosis to NGT [16] . Those studies included a relatively small number of patients, therefore, comparative analyses of particular MACE between the study groups were not performed. In a recent study by Mazurek et al. encompassing 2527 patients with AMI treated with percutaneous coronary intervention, with no specific exclusion criteria, patients with IGT or newly detected DM had a higher mortality than patients with isolated impaired fasting glycemia (IFG) or NGT and a similar prognosis to patients with previously known diabetes. The authors emphasized that the main finding of their study was that IGT negatively affected the treatment outcomes and that the long-term prognosis of patients with IGT was similar to those with DM. The analysis of particular MACE which occurred during long-term observation showed that there were no significant differences between patients with normal glucose tolerance and IFG, IGT, or DM with respect to recurrent AMI, percutaneous coronary intervention, coronary artery by-pass grafting or stroke [17] . The adverse role of IGT in AMI patients was also confirmed in a study by George et al. in which 42% of the study population was treated invasively [18] . Impaired glucose tolerance, as well as newly detected DM, were independent predictors MACE. Newly detected diabetes was also associated with a higher risk of nonfatal AMI. The authors compared readmission due to heart failure, however, no significant differences between the glucometabolic groups were noted [18] . To the authors' knowledge, there is only one study which showed that newly detected dysglycemia in AMI patients had no impact on the prognosis. Knudsen et al. showed that in patients treated invasively due to ST elevation AMI, the oral glucose tolerance test performed within 24 hours after hospital admission revealed that newly detected abnormal glucose regulation was prevalent in 47% of study subjects [19] . It was associated with older age, higher proportion of female gender, higher serum peak level of cardiac troponin, a larger myocardial infarct size measured as % of left ventricular mass three months later, significantly higher levels of glycosylated hemoglobin, insulin, proinsulin, C-peptide, and a higher homeostasis model assessment-estimated insulin resistance index (HOMA-IR) [19] . Although patients with abnormal glucose regulation were not started on glucose lowering medication, had a higher serum peak level of cardiac troponin, larger myocardial infarct size, and more severe glucometabolic derangement, their prognosis was similar to those with normogly-cemia [19] . The authors of the cited study suggested that a low prevalence of DM (24% of abnormal glucose regulation group and 11% of total study population) could have been related to the obtained results [19] . Patients with IFG were also included in the abnormal glucose regulation group, which could have resulted in a more favorable outcome. Nevertheless, early performance of OGTT, the exclusion of high-risk patients with heart failure and renal failure, which were shown to be independent risk factors of death in patients with glucose abnormalities [17] , could have had a major impact on the obtained results. In published studies, the clinical characteristics of patients with AMI and newly detected abnormal glucose tolerance are not equivocal, however, those patients are generally more likely to be older, female, hypertensive, overweight or obese, they have a worse left ventricle ejection fraction and renal function, higher glycemia measured on hospital admission, higher fasting glucose levels, higher glycosylated hemoglobin and insulin, proinsulin, and triglycerides than patients with normoglycemia [12, 13, 14, 15, 16, 17, 18, 19, 20, 21] . In the majority of studies there were no differences in cardiovascular medical history with respect to different glucose abnormalities, except a study by Bartnik et al. which showed that patients with abnormal glucose tolerance had a trend towards more heart failure history [21] . In summary, among patients with acute myocardial infarction, abnormal glucose tolerance is more likely to be detected in patients with other indices of disturbed glucose metabolism and comorbidities. Considering the fact that insulin resistance in patients with AMI during the in-hospital period significantly decrease from day 2 to day 5 and remain unchanged at 3--month follow-up [13] , OGTT should not be administered earlier than 4-5 days after AMI onset, as stated in ESC guidelines. OGTT performed early during the acute phase may have no prognostic significance due to acute hemodynamic and metabolic derangement, which may cause false positive results of the glucometabolic status. All the studies in which OGTT was performed as recommended showed that glucometabolic status, irrespective of the treatment strategy (invasive or conservative), indicate patients with different longterm risks of an adverse outcome. The basic characteristics of the cited studies are presented in Table I . Table II shows detailed data on the major adverse cardiovascular events reported in the cited studies.
Value of oral glucose tolerance test in stable patients after acute phase of myocardial infarctionnatural course and prognostic significance of glucose abnormalities
There are several studies in which the oral glucose tolerance test was repeated after the acute phase of myocardial infarction [12, 13, 14, 19, 20, 22, 23] . One of the first studies was conducted by Norhammar et al. who showed that at hospital discharge the prevalence of NGT, IGT or DM was: 34%, 35%, 31%, and 35%, 40%, 25% respectively after 3 months. There was a significant correlation between 2h-PG at discharge and 2h-PG after 3 months as well as for in-hospital HbA1c and 2h-PG at 3 months, and fasting blood glucose on day 4 and 2h-PG blood glucose at 3 months. The independent predictors of abnormal glucose tolerance after 3 months were glycosylated hemoglobin and fasting blood glucose at discharge, however, no predictive values of those parameters were established [12] . The authors also did not distinguish risk factors for the persistence of newly detected abnormal glucose tolerance at follow-up. Wallander et al. reported the prevalence of NGT, IGT or DM at hospital discharge, after 3 months and at 12--month follow-up in 122 subjects with AMI [14] . Among those with abnormal glucose tolerance at discharge, 78% still had AGT after 3 months and 83% at the 12-month follow-up. Even though, compared to hospital discharge, 49% of patients were in the same glucometabolic category after 3 months and 56% after one year, the authors concluded that OGTT performed in AMI patients at hospital discharge reliably indicated the long-term glucometabolic state [14] . In a study by Tenerz et al., among 94 patients with AGT at discharge 73% had AGT after 3 months [13] . The analysis of insulin resistance showed that it was significantly higher at day two of index hospitalization due to AMI compared to day 5, however, no significant difference was observed between day 5 and 3--month follow-up. The authors concluded that OGTT performed at discharge from hospital provides a reliable estimate of diabetes classified 3 months after AMI [7] . Nevertheless, they also indicated that intraindividual tracking of oral glucose tolerance from discharge to follow-up was fairly poor, therefore, they recommended repeating OGTT to identify true-risk individuals [13] . Some authors state that a single test is sufficient for epidemiological and screening purposes, but to establish the diagnosis it should be repeated [24, 25, 26] . Another study, in which OGTT was repeated 3 months after the first AMI, was conducted by Bronisz et al. [14] . It showed that in patients after the first ST elevation AMI, abnormal glucose tolerance at discharge was transient in 55% of subjects at follow-up. The authors did not extract the risk factors for the persistence of glucose abnormalities, but revealed that age > 77 years, 2h-PG ≥ 12.06 mmol/l and mean blood glucose level on day 2 > 7.5 mmol/l were independent predictors of disturbances in glucose metabolism at the 3-month follow-up. Unlike in other cited studies, glycosylated hemoglobin only weakly correlated with 2h-PG at discharge, and the impact of HbA1c on the result of OGTT at 3 months was not observed. As previously mentioned, Knudsen et al. performed the oral glucose tolerance test within 24 hours after hospital admission in patients with ST elevation AMI treated invasively and repeated it after 3 months. At 3--month follow-up abnormal glucose tolerance was transient in 68% of subjects, which was the highest value among the cited studies in which OGTT was repeated. Glycosylated hemoglobin and glycemia on admission to the hospital analysed separately, after adjustment for confounders, remained significant predictive factors for abnormal glucose regulation at follow-up [22] . This is the only study in which the authors showed the significant role of glycemia measured on admission to the hospital as a prognostic marker of the post-AMI glucometabolic status. Studies in which patients with admission hyperglycemia (≥ 11.1 mmol/l) were not excluded showed that admission glycemia was not a useful marker of disturbances in glucose metabolism at follow-up. In all of those studies OGTT was performed shortly before or at discharge. The changes in the prevalence of different glucose abnormalities in the cited studies with repeated OGTT are shown in Table III. More recently, two studies were published in which the oral glucose tolerance test was performed in post-AMI patients during a stable condition. Henareh et al. studied 123 patients without a history of diabetes who had experienced AMI 3-12 months before the study [27] . Not all the patients had a coronary angiography, in some of them it showed no significant stenoses, and there were also patients treated with thrombolysis only. The study did not show an increased risk of MACE in patients with diabetes mellitus or impaired glucose tolerance compared to patients with normal glucose tolerance. However, an increase in 2h-PG was independently associated with long-term MACE. In a study conducted by our group, 368 patients with AMI treated invasively in whom the oral glucose tolerance test was performed at hospital discharge and who completed a follow-up ambulatory visit with repeated OGTT after 6 months, were analyzed with respect to changes in the glucometabolic status [23] . Out of 149 patients with AGT at discharge 68% still had AGT after 6 months. A high value of 2h-PG at discharge and high fasting glycemia were significant risk factors for sustained AGT. Analysis of the receiver-operator characteristic curves showed that the highest area under the curve was calculated for 2h-PG with a cut-off concentration of 10.2 mmol/l, and that glycemia measured at the time of hospital admission had no significant value in predicting the persistence of AGT. Moreover, 52% of subjects with normal glucose tolerance NGT at discharge developed AGT after 6 months. The reported changes in prevalence were 
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Kitada et al. 16 2-year event-free rate of patients with 2h-PG ≥ 160 mg/dL was significantly higher than that of patients with 2h-PG < 160 mg/dL and was similar to that of patients with previous diabetes. 2h-PG ≥ 160 mg/dL was only independent predictor of long--term MACE (recorded after 30 days of AMI). MACE were defined as: death from cardiovascular causes, nonfatal AMI, hospitalization for heart failure and revascularization for restenosis and de novo lesions.
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Mazurek et al. 17 in those patients was independent risk factor of death.
Event was not analyzed.
Abbreviations: MACE = major adverse cardiovascular events; AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery by-pass grafting; ACS = acute coronary syndrome; 2h-PG = two-hour post-load glycemia; IGT-impaired glucose tolerance; DM = diabetes mellitus; IFG = impaired fasting glycemia; NGT = normal glucose tolerance; HbA1c = glycosylated hemoglobin. year was even better than after 3 months (AGTAGT: 83%; NGTNGT: 60%). One can conclude that there is more agreement between two oral glucose tolerance tests performed in-hospital and after discharge in studies which include both STEMI and NSTEMI patients, do not exclude patients with heart failure, in which OGTT is repeated at longer intervals, and most importantly, OGTT is performed not earlier than on the 4 th day after admission to hospital. A higher rate of invasive treatment appears to have no impact on changes in the glucometabolic status after hospital discharge. In the study by our group patients with persistent AGT had a significantly higher mortality than subjects with transient AGT. Newly detected AGT was associated with higher mortality than persistent NGT, however, this difference was statistically non-significant during the follow-up period. More importantly, none of the glycemic parameters measured in-hospital (admission, fasting, and 2h post load glycemia) had the ability to predict a new onset of AGT. To the authors knowledge this is the only published study which shows the prognostic usefulness of repeated oral glucose tolerance test in patients with AMI treated invasively. Whether its prognostic implications are observed because of more glucometabolic derangement or a high prevalence of comorbidities is not known. Nevertheless, the importance of repeated OGTT after acute coronary syndrome is elusive and not mentioned in the most recent ESC guidelines. Moreover, one can assume that repeated OGTT in patients with newly detected diabetes mellitus, although performed in many studies, is controversial.
Hypoglycemic treatment in patients with AMI and newly detected abnormal glucose tolerancetherapeutic concerns
Data on secondary prevention after AMI with respect to antidiabetic treatment in patients with newly detected abnormal glucose tolerance are scarce, therefore, most recommendations are based on studies encompassing patients with stable coronary artery disease and diabetes with a low proportion of subjects with newly detected diabetes. It should be emphasized that in published studies the patients were frequently defined as having DM if diabetes had been known before hospital admission or if it was diagnosed by admission glycemia ≥11.1 mmol/l. Therefore, a substantial number of patients with diabetes that would have been detected by OGTT at hospital discharge were not included. Moreover, in those studies the proportion of patients after AMI, and patients treated with percutaneous coronary intervention was relatively low. Lifestyle modification (appropriate diet, exercise, smoking cessation, weight reduction) after AMI was associated with a substantially lower risk of diabetes onset or recurrent cardiovascular events [28, 29, 30] . In patients with impaired glucose tolerance, lifestyle intervention was associated with a lower incidence of newly detected diabetes mellitus and reduced cardiovascular mortality [31] . Conversion to normal glucose regulation, even if transient, was associated with a lower long-term cardiovascular risk in patients with prediabetes [32] . In men with AMI and impaired glucose tolerance there was a beneficial effect of regular physical training on reducing fasting insulinemia [33] . Schramm et al. analyzed the mortality and cardiovascular risk of adults initiating a single-agent: insulin secretagogues or metformin [34] . Monotherapy with one of the most commonly used drugs: glimepiride, glibenclamide, glipizide, and tolbutamide, seemed to be related to a higher mortality and cardiovascular risk compared with metformin, however, gliclazide and repaglinide appeared to be associated with a lower risk than treatment with the remainder of this group and a comparable risk to those treated with metformin. Those results were similar in patients with previous AMI [34] . The authors of the DIGAMI II study in diabetic patients with AMI, allocated to three treatment arms, reported that neither all-cause mortality nor morbidity differed between the three groups [35] . In a post hoc analysis of this study the authors concluded that although there were no differences in mortality between diabetic patients treated with sulphonylureas, metformin, and insulin, the risk of non-fatal myocardial infarction or stroke was higher in patients on insulin treatment, while metformin seemed to be protective [36] . Anselmino et al. showed that there was a pronounced decrease in cardiovascular events in patients with coronary artery disease and prescribed glucose lowering drugs for newly detected diabetes mellitus compared with those not receiving such treatment [37] . In a study by Abualsuod et al., the use of metformin in patients with diabetes was associated with a lower 30-day all-cause mortality and tendency for a lower 12-month all-cause mortality following AMI [38] . Hage et al. showed that sitagliptin improved beta-cell function and glucose perturbations in patients with acute coronary syndromes and newly diagnosed abnormal glucose tolerance [39] . Acarbose reduced the risk of MACE in patients with acute coronary syndromes and newly detected impaired glucose tolerance [40] . In patients with coronary artery disease and newly detected abnormal glucose tolerance, 6month therapy with eicosapentaenoic acid corrected postprandial hypertriglyceridemia, hyperglycemia and insulin secretion ability. This amelioration of several metabolic abnormalities was accompanied by recovery from concomitant endothelial dysfunction [41] . Recent ESC guidelines on cardiovascular prevention advocate lifestyle changes, blood pressure and dyslipidemia management, for all patients with diabetes and metformin as first line therapy of type 2 DM, if tolerated and not contra-indicated [42] . A target of glycated hemoglobin of < 7% is recommended for the majority of adults, however, in patients with cardiovascular disease less stringent targets could be considered. Guidelines on diabetes and prediabetes advocate intensive blood pressure and dyslipidemia management, as well as glycosylated hemoglobin < 7% for patients with cardiovascular disease and diabetes or impaired glucose tolerance [43] . Nonetheless, considering the fact that in some patients with AMI newly detected abnormal glucose tolerance is transient, there is a risk of overdiagnosis and overtreatment. Studies in which a transient pattern of disturbed glucose metabolism was observed, have not evaluated whether changes in the glucometabolic status following AMI were a result of good adherence to lifestyle and behavioral advice. In the light of this hypothesis, a very interesting study conducted by Steven et al. should be cited. The authors stated that in patients who responded to a very low calorie diet, type 2 diabetes mellitus was a reversible condition [44] . Whether such a strict diet regimen would be beneficial in terms of cardiovascular outcome in patients after AMI is not known.
CO NC LU SI O N S
The oral glucose tolerance test should be done in all patients with acute myocardial infarction. The appropriate moment to perform OGTT is crucial for this test to accomplish its role not only as a predictor of longterm glucometabolic status, but also as a valuable prognostic tool. The use of other glucometabolic parameters like fasting glycemia or glycosylated hemoglobin may be used to assess the risk of persistent abnormal glucose tolerance, however OGTT may be repeated to prevent overdiagnosis of AGT, improve initial risk stratification and select "true" high-risk individuals. In all patients with AMI and abnormal glucose tolerance, lifestyle modification should be advised, and intensive treatment of dyslipidemia and high blood pressure initiated according to AMI guidelines. Whether, when and in which patients hypoglycemic pharmacotherapy should be initiated is elusive. Nevertheless, according to the guidelines metformin should be the first line medication.
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